|
|
||||||||
Article |
Laboratory of Experimental Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium (A.H., B.L., A.T.V.O., E.A.D.B.); and Department of Cancer Medicine, Ninewells Hospital, Dundee, United Kingdom (M.S.H.)
Abstract
Abstract I. Introduction II. Vascular Endothelial Growth Factor A. The Locations and Structures of Vascular Endothelial Growth Factor B. Vascular Endothelial Growth Factor Receptors C. Signal Transduction D. Regulation of Gene Expression E. Physiological Regulation of Vascular Endothelial Growth Factor in Normal Adults III. Vascular Endothelial Growth Factor in Tumor Growth A. Vascular Endothelial Growth Factor and Tumorigenesis B. Lymphangiogenesis and Tumor Growth C. The Role of Vascular Endothelial Growth Factor in the Impaired Host Antitumor Immune Response D. Vascular Endothelial Growth Factor as a Prognostic Factor or an Indicator of Angiogenesis E. Potential Therapeutic Applications Related to Vascular Endothelial Growth Factor IV. Vascular Endothelial Growth Factor in Nonmalignant Disease A. Rheumatoid Arthritis and Osteoarthritis B. Cardiovascular Ischemia C. Peripheral Vascular Disease D. Diabetes Mellitus E. Endometriosis, Preeclampsia, and Ovarian Hyperstimulation Syndrome F. Psoriatic Skin Disease V. Conclusions and Future Directions
Angiogenesis is a hallmark of wound healing, the menstrual cycle, cancer, and various ischemic and inflammatory diseases. A rich variety of pro- and antiangiogenic molecules have already been discovered. Vascular endothelial growth factor (VEGF) is an interesting inducer of angiogenesis and lymphangiogenesis, because it is a highly specific mitogen for endothelial cells. Signal transduction involves binding to tyrosine kinase receptors and results in endothelial cell proliferation, migration, and new vessel formation. In this article, the role of VEGF in physiological and pathological processes is reviewed. We also discuss how modulation of VEGF expression creates new therapeutic possibilities and describe recent developments in this field.
This article has been cited by other articles:
![]() |
F. Memarzadeh, R. Varma, L.-T. Lin, J. G. Parikh, L. Dustin, A. Alcaraz, and D. Eliott Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3233 - 3237. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Eto, M. Miyagishi, R. Inagi, T. Fujita, and M. Nangaku Mitogen-Activated Protein 3 Kinase 6 Mediates Angiogenic and Tumorigenic Effects via Vascular Endothelial Growth Factor Expression Am. J. Pathol., April 1, 2009; 174(4): 1553 - 1563. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hvid, I. Teige, P. H. Kvist, L. Svensson, and K. Kemp TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis Int. Immunol., August 1, 2008; 20(8): 1097 - 1106. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Kim, D. K. Hahn, C. P. Kellner, Z. L. Hickman, R. J. Komotar, R. M. Starke, W. J. Mack, J. Mocco, R. A. Solomon, and E. S. Connolly Jr Plasma Levels of Vascular Endothelial Growth Factor After Treatment for Cerebral Arteriovenous Malformations Stroke, August 1, 2008; 39(8): 2274 - 2279. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C.A. Stene, R. Frikke-Schmidt, B. G. Nordestgaard, P. Grande, P. Schnohr, and A. Tybjaerg-Hansen Functional Promoter Variant in Zinc Finger Protein 202 Predicts Severe Atherosclerosis and Ischemic Heart Disease J. Am. Coll. Cardiol., July 29, 2008; 52(5): 369 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guruvayoorappan and G. Kuttan (+)-Catechin inhibits tumour angiogenesis and regulates the production of nitric oxide and TNF-{alpha} in LPS-stimulated macrophages Innate Immunity, June 1, 2008; 14(3): 160 - 174. [Abstract] [PDF] |
||||
![]() |
J. Shen and P. E. DiCorleto ADP Stimulates Human Endothelial Cell Migration via P2Y1 Nucleotide Receptor-Mediated Mitogen-Activated Protein Kinase Pathways Circ. Res., February 29, 2008; 102(4): 448 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kolev, H. Uetake, S. Iida, T. Ishikawa, T. Kawano, and K. Sugihara Prognostic Significance of VEGF Expression in Correlation With COX-2, Microvessel Density, and Clinicopathological Characteristics in Human Gastric Carcinoma Ann. Surg. Oncol., October 1, 2007; 14(10): 2738 - 2747. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guruvayoorappan and G. Kuttan {beta}-Carotene Inhibits Tumor-Specific Angiogenesis by Altering the Cytokine Profile and Inhibits the Nuclear Translocation of Transcription Factors in B16F-10 Melanoma Cells Integr Cancer Ther, September 1, 2007; 6(3): 258 - 270. [Abstract] [PDF] |
||||
![]() |
C. Guruvayoorappan and G. Kuttan Effect of Amentoflavone on the Inhibition of Pulmonary Metastasis Induced by B16F-10 Melanoma Cells in C57BL/6 Mice Integr Cancer Ther, June 1, 2007; 6(2): 185 - 197. [Abstract] [PDF] |
||||
![]() |
D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yin, K.-i. Morishige, T. Takahashi, K. Hashimoto, S. Ogata, S. Tsutsumi, K. Takata, T. Ohta, J. Kawagoe, K. Takahashi, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo Mol. Cancer Ther., May 1, 2007; 6(5): 1517 - 1525. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saito, A. Sugawara, A. Uruno, M. Kudo, H. Kagechika, Y. Sato, Y. Owada, H. Kondo, M. Sato, M. Kurabayashi, et al. All-trans Retinoic Acid Induces in Vitro Angiogenesis via Retinoic Acid Receptor: Possible Involvement of Paracrine Effects of Endogenous Vascular Endothelial Growth Factor Signaling Endocrinology, March 1, 2007; 148(3): 1412 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Piqueras, A. R. Reynolds, K. M. Hodivala-Dilke, A. Alfranca, J. M. Redondo, T. Hatae, T. Tanabe, T. D. Warner, and D. Bishop-Bailey Activation of PPAR{beta}/{delta} Induces Endothelial Cell Proliferation and Angiogenesis Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 63 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cowey and R. W. Hardy The Metabolic Syndrome: A High-Risk State for Cancer? Am. J. Pathol., November 1, 2006; 169(5): 1505 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. N. Bochkov, M. Philippova, O. Oskolkova, A. Kadl, A. Furnkranz, E. Karabeg, T. Afonyushkin, F. Gruber, J. Breuss, A. Minchenko, et al. Oxidized Phospholipids Stimulate Angiogenesis Via Autocrine Mechanisms, Implicating a Novel Role for Lipid Oxidation in the Evolution of Atherosclerotic Lesions Circ. Res., October 13, 2006; 99(8): 900 - 908. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ispanovic and T. L. Haas JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells Am J Physiol Cell Physiol, October 1, 2006; 291(4): C579 - C588. [Abstract] [Full Text] [PDF] |
||||
![]() |
S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Benakanakere, C. Besch-Williford, J. Schnell, S. Brandt, M. R. Ellersieck, A. Molinolo, and S. M. Hyder Natural and Synthetic Progestins Accelerate 7,12-Dimethylbenz[a]Anthracene-Initiated Mammary Tumors and Increase Angiogenesis in Sprague-Dawley Rats. Clin. Cancer Res., July 1, 2006; 12(13): 4062 - 4071. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Fath, X. Kong, D. Liang, Z. Lin, A. Chou, Y. Jiang, J. Fang, J. Caro, and N. Sang Histone Deacetylase Inhibitors Repress the Transactivation Potential of Hypoxia-inducible Factors Independently of Direct Acetylation of HIF-{alpha} J. Biol. Chem., May 12, 2006; 281(19): 13612 - 13619. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Tomanek, Y. Ishii, J. S. Holifield, C. L. Sjogren, H. K. Hansen, and T. Mikawa VEGF Family Members Regulate Myocardial Tubulogenesis and Coronary Artery Formation in the Embryo Circ. Res., April 14, 2006; 98(7): 947 - 953. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, Q. Hu, A. Mansoor, J. Lee, Z. Wang, T. Lee, A. H. L. From, and J. Zhang Bioenergetic and functional consequences of stem cell-based VEGF delivery in pressure-overloaded swine hearts Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1393 - H1405. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Voelkel, R. W. Vandivier, and R. M. Tuder Vascular endothelial growth factor in the lung Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L209 - L221. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Menendez, O. Krysiak, A. Inga, B. Krysiak, M. A. Resnick, and G. Schonfelder A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network PNAS, January 31, 2006; 103(5): 1406 - 1411. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Lindsey, G. P. Escobar, L. W. Dobrucki, D. K. Goshorn, S. Bouges, J. T. Mingoia, D. M. McClister Jr., H. Su, J. Gannon, C. MacGillivray, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H232 - H239. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |